Show Me the Value
This article was originally published in RPM Report
Executive Summary
As cancer drug prices approach $100,000, manufacturers are facing strong resistance from manufacturers. Now Wall Street is starting to worry.
You may also be interested in...
Medicare Research Priorities: A Taste Of What's To Come?
Any government-sponsored center on comparative effectiveness will focus on the research priorities of the Medicare and Medicaid programs as a way to lower health care costs. The findings of a Medicare coverage advisory committee offers a glimpse of where those priorities may fall.
Reimbursing Designer Drugs
Now that FDA is pushing a regulatory pathway for personalized medicine through the Critical Path initiative, the next step for industry should be securing payment, especially given what could be relatively high price tags. So what are payors--and the biggest payor of all, CMS--doing to prepare? The answer is, not much.
Reimbursing Designer Drugs
Now that FDA is pushing a regulatory pathway for personalized medicine through the Critical Path initiative, the next step for industry should be securing payment, especially given what could be relatively high price tags. So what are payors--and the biggest payor of all, CMS--doing to prepare? The answer is, not much.